Cervical Cancer and the Immune System

Ritu Salani, M.D., M.B.A. Professor Gynecologic Oncologist UCLA



Objectives

- Primary Prevention
 - Screening recommendations
 - Vaccination

• Treatment

- Recurrent treatment
- Frontline
 - Advanced/Metastatic
 - Chemoradiation
- Novel combinations



Cervical Cancer HPV Infection



Cervical Cancer Screening



- HPV: at age 25 (primary or co-testing)
 - Can discontinue at age 65 if appropriate negative screening
 - Still accounts for ~20% of cases (more advanced stages)
 - \$83 million (unnecessary) cost attributed to screening in this population
- Screening detects 52% of cases
 - Failure to screen, failure to detect or failure to follow up
 - Disparities




Long control reg


HPV-16

HPV Infection

- Cancer causing HPV infection
 - 1 in 5 women




HPV CAUSES SIX TYPES OF CANCER






HPV Vaccination

- Ages 9-45 years eligible
 - 11-12 years (ideal)
- Over 300 million doses given



Vaccine hesitancy



Study of young cancer survivors


- •71% refuse vaccine
 - Safety, disinterest, knowledge



Cervical Cancer and HPV Vaccination

- Study of 1,672,983 girls and women ages 10-30
 - 527,871 received at least one dose of HPV vaccine

HPV vaccine	Incidence rate ratio		
Before age 17	0.12		
Ages 17-30	0.47		





WHO Global Call for Action 2018: Eliminate Cervical Cancer

- Vaccinate 90% of girls by age 15
- Screen 70% of women with high performance test by age 35
- Maintain an incidence rate below 4 per 100,000 women
- Treat 90% women with precancerous and invasive cancer
- These interventions will lower incidence by 97% by 2120
 - 62 million deaths averted





Cervical Cancer The Age of Immunotherapy



Cervical Cancer Incidence and Mortality


- Worldwide: 604,127 new cases and 341,831 deaths
- US: 14,100 cases and 4,280 deaths All Races (incl Hisp) Hispanic (any race Rate of new cases Deaths per 100,000 resident population persons Black (incl Hisp) Death rate White (incl Hisp) 100,000 per Rate Year of Death

UCLA Health

SEER.cancer.gov; https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21660. Cibula D. Gynecol Oncol 2022;164.

Rationale for Immunotherapy


- TCGA data
 - Amplifications in PD-L1 and PD-L2
 - Correlates with key immune cytolytic effectors
 - Can limit protective immunity
- PD-1/PD-L1 inhibition
 - Promote T cell activation against tumor





Biomarkers for Cervical Cancer

- PD-L1 expression: 60-90%
- Combined Positive Score (CPS) \geq 1
 - Number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) to all tumor cells




- TMB-high: 6%
- MMRd/MSI status: 3-14%



Meng Y, et al. J Cancer. 2018. Enwere E, et al. Mod Pathol. 2017. Zhang L, et al. N Engl J Med. 2003. Yarchoan M, et al. N Engl J Med. 2017. Kulangara K, et al. Arch Pathol Lab Med. 2019. Chung TK, et al. Gynecol Obstet Invest. 2001. Bonneville R, et al. JCO Precis Oncol. 2017.

Cervical Cancer: Treatment Overview



UCLA Health

National Cancer Institute [cancer.gov]. Accessed August 4, 2022. https://seer.cancer.gov/statfacts/html/cervix.html.

Recurrent Disease: Immunotherapy


	Ν	PD-L1 rate	RR in PDL1+	DoR	PFS (mo)	OS (mo)
Pembrolizumab	98	77%	17.1%	NR	3	11
Cemiplimab	304	-	21.1%	16.4	2.9	12
Balstilimab	138	61%	20%	18.4		
Nivolumab/Ipilimumab	45	58%	39%	25.6		20.9
Balstilimab/Zalifrelimab	143	51%	32.8%	NR	2.7	12.8



Chung HC, et al. *J Clin Oncol.* 2019. Tewari KS, et al. *N Engl J Med.* 2022. Oaknin ESMO 2022. Omalley JCO 2021; Omalley Gyn Oncol 2021. Oaknin ESMO 2022.

First-line treatment: KEYNOTE 826

- Persistent, recurrent, or metastatic cervical cancer
- No prior systemic chemotherapy
- ECOG PS 0-1




	Pembrolizumab group (n=308)	Placebo group (n=309)
Age, median (range), y	51 (25-82)	50 (22-79)
ECOG PS 1, No. (%)	128 (42)	139 (45)
SCC, No. (%)	235 (76)	211 (68)
PD-L1 CPS, No. (%)		
<1	35 (11)	34 (11)
1 to <10	115 (37)	116 (38)
≥10	158 (51)	159 (51)
Bevacizumab use during trial, No. (%)	196 (64)	193 (62)

Endpoints

- Dual primary: OS and PFS
- Secondary: ORR, DOR, 12-mo PFS, and safety



KEYNOTE 826: Progression Free Survival




PD-L1 CPS ≥10 HR 0.58 (95% CI, 0.44-0.77); *P*<0.001



Colombo N, et al. N Engl J Med. 2021.

KEYNOTE 826: Overall Survival





Colombo N, et al. N Engl J Med. 2021.

Outcomes by subgroup

Progression Free Survival

CPS ≥1

No. of Events/ No. of Participants			Hazard Ratio (95% Cl)		
Overall	355/548	——	0.62 (0.50-0.77)		
Histology					
Squamous	269/409		0.61 (0.48-0.78)		
Non-squamous	85/138		0.59 (0.37-0.93)		
Platinum use					
Carboplatin	293/447	——	0.68 (0.53-0.85)		
Cisplatin	61/99		0.39 (0.22-0.68)		
Concomitant bevaci	izumab				
Yes	203/346		0.61 (0.46-0.80)		
No	152/202		0.66 (0.47-0.92)		
Prior CRT					
Yes	142/215	———	0.55 (0.39-0.78)		
No	213/333		0.68 (0.52-0.90)		
	0.25	•••	.0 2.0 4.0 i o (95% CI)		
		avors	Favors		
		o + Chemo Bev	Pbo + Chemo		
		Dev	±Bev		


Overall Survival

CPS ≥1

No. of Events/ No. of Participants			Hazard Ratio (95% Cl)		
Overall	272/548		0.64	(0.50-0.81)	
Histology					
Squamous	213/409		0.60	(0.46-0.79)	
Non-squamous	59/138		0.70	(0.41-1.20)	
Platinum use					
Carboplatin	231/447		0.65	(0.50-0.85)	
Cisplatin	39/99	-	0.53	(0.27-1.04)	
Concomitant bevaciz	umab				
Yes	143/346		0.62	(0.45-0.87)	
No	129/202		0.67	(0.47-0.96)	
Prior CRT					
Yes	118/215		0.56	(0.39-0.81)	
No	154/333		0.72	(0.52-1.00)	
	0.25	0.5 1.0	0 2.0	4.0	
	Hazard Ratio (95% CI)			_	
		Favors	Favors		
	Pemi	tBev	Pbo + Chem ±Bev	10	

UCLA Health

Cervical Cancer: Treatment Overview






National Cancer Institute [cancer.gov]. Accessed August 4, 2022. https://seer.cancer.gov/statfacts/html/cervix.html.

Locally Advanced Cervical Cancer

- Chemoradiation and brachytherapy
 - PFS and OS ~60-70%









Morris M, et al. *N Engl J Med*. 1999. Stehman FB, et al. *Am J Obstet Gynecol*. 1998. Whitney CW, et al. *J Clin Oncol*. 1999. Duenas-Gonzalez A, et al. *J Clin Oncol*. 2011. Peters WA 3rd, et al. *J Clin Oncol*. 2000. Rose PG, et al. *N Engl J Med*. 1999.

CALLA: Durvalumab and Chemoradiation





KEYNOTE A18/GOG 3047: Pembrolizumab and Chemoradiation




UCLA Health

Cervical Cancer The Future



Recurrent Disease: Ongoing Studies



Recurrent Disease: Ongoing Studies

Immunotherapy Combinations		
Tisotumab + Pembrolizumab	38% ORR	
TILs (LN-145)**	44% ORR	
Cadonilimab (PD-1/CTLA4 bispecific)	33% ORR	
Atezolizumab +/- Tiragolumab	Study closed	
DNA Vaccines		
GX-188E + Pembrolizumab	32% ORR	
VB10.16 + Checkpoint Inhibitor**	In Development	

• **Prior checkpoint inhibitor therapy



Conclusions

- The immune system is critical in cervical cancer development and treatment
- Screening and prevention should be prioritized
 - HPV Vaccination can reduce the risk of cancer by ~80%
- Checkpoint inhibitor therapy is transforming treatment options
 - In frontline and be investigated in locally advanced cervical cancer
- Novel combinations are being further explored



Thank you

rsalani@mednet.ucla.edu



"It's always Sit, Stay, Heel - never Think, Innovate, Be yourself."

